Introduction CIDP is a chronic immune-mediated neuropathy characterized by progressive weakness, sensory loss, and functional disability. Standard treatments such as IVIg, corticosteroids, and plasma exchange may offer benefit but are associated with relapse, incomplete response, or treatment dependency. Riliprubart, a monoclonal antibody targeting